ASMC'11 St. Petersburg
Confirmed Speakers
 Metal-Catalyzed C–H Bond Functionalizations for Sustainable Synthesis
Prof. Lutz ACKERMANN
(GEORG-AUGUST UNIVERSITY GOETTINGEN, Goettingen, Germany)
 Chemical Probes for Epigenetics
Dr Mark BUNNAGE
(PFIZER, Canterbury, Kent, United States)
 Novel Metabotropic Glutamate Receptor 4 (mGluR4) Allosteric Potentiators for the Treatment of Parkinsons’s Disease
Dr Sylvain CELANIRE
(ADDEX PHARMACEUTICALS, Geneva, Switzerland)
 A few of my Favorite Rings: Catalysis Inspired by Lactones and Lactams
Prof. Vy M. DONG
(UNIVERSITY OF TORONTO, Toronto, Canada)
 Tofacitinib (CP-690,550): Discovery of a Potent and Selective JAK Inhibitor
Dr Mark FLANAGAN
(PFIZER, Connecticut, United States)
 Antibody Directed Cytotoxics
Prof. John FLYGARE
(GENENTECH, California, United States)
 From Homer to Hedgehog: Chemistry, Biological Investigations and Medical Perspectives of Cyclopamine
Prof. Athanassios GIANNIS
(UNIVERSITY OF LEIPZIG, Leipzig, Germany)
 Bicyclic Peptides with Tailored Binding Specificities for Therapeutic Application
Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)
 Regioselective Reactions on a Chiral Substrate Controlled by the Configuration of a Chiral Catalyst
Prof. Henri KAGAN
(UNIVERSITY PARIS-SUD 11, ORSAY Cedex, France)
 Discovery and Development of Novel Antimalarials
Dr Rodney KIP GUY
(ST. JUDE CHILDREN'S RESEARCH HOSPITAL, Memphis, United States)
 Target Synthesis Directed Methodology Development
Prof. Dawei MA
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China)
 Minor Enantiomer Recycling – A Strategy for Improving Enantioselectivity
Prof. Christina MOBERG
(KTH SCHOOL OF CHEMICAL SCIENCE AND ENGINEERING, Stockholm, Sweden)
 Magical Power of d-Block Transition Metals—Pd-Catalyzed Cross-Coupling and Zr-Catalyzed Asymmetric carboalumination of Alkenes (ZACA)
Prof. Ei-ichi NEGISHI
(PURDUE UNIVERSITY, West Lafayette, United States)
 Maitotoxin. An Inspiration for Synthesis
Prof. K.C. NICOLAOU
(THE SCRIPPS RESEARCH INSTITUTE & UNIVERSITY OF CALIFORNIA, Houston, United States)
 Small Molecules Inhibitors of the WNT Signalling Pathway with Potential Applications in Oncology
Dr Alessandro PADOVA
(SIENA BIOTECH, Siena, Italy)
 Design Strategy for Preparation of Drug-like Polyheterocycles with Privileged Substructures for Discovery of Specific Small Molecule Modulators
Prof. Seung Bum PARK
(SEOUL NATIONAL UNIVERSITY, Seoul, Korea, South)
 Synthesis of Marine Polyketides as Promising Anticancer Agents
Prof. Ian PATERSON
(CAMBRIDGE UNIVERSITY, Cambridge, United Kingdom)
 GPR119: Knowledge Based Lead Identification
Dr Sherrie L. PIETRANICO-COLE
(ROCHE, NUTLEY NJ, United States)
 A Step Closer to Hepatitis C Remedy: TMC435, an HCV Protease Inhibitor in Advanced Clinical Trial
Dr Pierre RABOISSON
(JANSSEN INFECTIOUS DISEASES, Beerse, Belgium)
 The Many Uses of Noncovalent Mass Spectrometry in Early-stage Drug Discovery
Dr Jean-Paul RENAUD
(NOVALIX, Illkirch, France)
 The Resurgence of Covalent Drugs
Dr Juswinder SINGH
(AVILA THERAPEUTICS, WALTHAM, United States)
 Lessons in Chemoselectivity: Total Synthesis of Polyphenolic Natural Products
Prof. Scott SNYDER
(COLUMBIA UNIVERSITY, New York, United States)
 Asymmetric Synthesis of Bioactive Molecules
Prof. Mikiko SODEOKA
(RIKEN, Hirosawa, Japan)
 Biochemical Efficiency, a Metrics for an Optimal Molecular Mechanism of Action
Dr David SWINNEY
(IRND3, Mountain View, United States)
 Drug Discovery by Programmed Self-Assembly
Prof. Nicolas WINSSINGER
(UNIVERSITY OF STRASBOURG, Geneva, Switzerland)
 Bromodomains a New Class of Epigenetic Targets Ripe for Small Molecule Drug Discovery
Dr Jason WITHERINGTON
(GLAXOSMITHKLINE R&D, Stevenage, United Kingdom)
 Validation of N-Myristoyltransferase as a Drug Target
Prof. Paul WYATT
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)
 Accelerated C-H Activation Reactions: Enantioselectivity and Positional Selectivity
Prof Jin-Quan YU
(THE SCRIPPS RESEARCH INSTITUTE, La Jolla, United States)
Selected Oral Communications
 Small Molecule Inhibitors of the Neuropilin-1 VEGF-A Interaction
Dr Philip FALLON
(DOMAINEX, Cambridge, United Kingdom)
 Halogen Bonding in Protein–ligand Interactions
Mr Leo HARDEGGER
(ETH ZURICH, Zürich, Switzerland)
 The Chemical Biology Consortium- and Experimental Therapeutics Program
Dr Sanjay MALHOTRA
(NATIONAL CANCER INSTITUTE, Frederick, United States)
 Adventures in Medicinal Chemistry and Knowledge Capture
Dr Alexander MAYWEG
(F. HOFFMANN-LA ROCHE LTD, BASEL, Switzerland)
 Identification of Bisaryloxy Azetidine Urea Derivatives as Fatty Acid Amide Hydrolase Inhibitors
Dr Hans MEISSNER
(VERNALIS, Cambridge, United Kingdom)
 Identification of Leads from the Tres Cantos Antimalarial Set: Cyclopropyl Carboxamides Show Good Oral Bioavailability and Efficacy In Malarial Animal Models
Mrs Maria Lourdes RUEDA-BENEDE
(GLAXOSMITHKLINE, Tres Cantos, Spain)
 Highly Efficient Catalytic System for C-H Activation: A Novel and Practical Synthesis of Angiotensin II Receptor Blockers
Dr Masahiko SEKI
(MITSUBISHI TANABE PHARMA CORPORATION, Fukuoka, Japan)
 The Grandisine Alkaloids as Selective δ-Opioid Receptor Agonists; When is a Natural Product not a Natural Product?
Prof. Richard TAYLOR
(UNIVERSITY OF YORK, York, United Kingdom)
 Exploring the Rigid Mono- and Diamine Chemical Space
Dr Dmytro VOLOCHNYUK
(ENAMINE LTD., Kiev, Ukraine)
 Lead identification of a new class of P2Y12 inhibitors "From a low active and insoluble HTS hit to soluble and active lead compounds"
Mr Fredrik ZETTERBERG
(ASTRAZENECA, Gothenburg, Sweden)
 The Chemistry of Targeting Protein-Protein Interactions: Thinking Outdside of the Box
Dr Giovanna ZINZALLA
(LONDON SCHOOL OF PHARMACY, London, United Kingdom)
<Previous page


Organised by

and

With the support of

Sponsors

Media Partners